251 – 260 of 329
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2003
-
Mark
On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome.
(
- Contribution to journal › Article
-
Mark
Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay
(
- Contribution to journal › Article
-
Mark
Prophylactic therapy for haemophilia: early experience.
(
- Contribution to journal › Article
-
Mark
Elective orthopaedic surgery for inhibitor patients.
(
- Contribution to journal › Article
-
Mark
Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.
(
- Contribution to journal › Article
-
Mark
Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population
(
- Contribution to journal › Article
-
Mark
Limited protective effect of the CCR5 Delta 32/CCR5 Delta 32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus
(
- Contribution to journal › Article
-
Mark
A Healthy Hemophilic Patient without Arthropathy: From Concept to Clinical Reality.
(
- Contribution to journal › Article
-
Mark
Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance?
(
- Contribution to journal › Article
-
Mark
Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin.
(
- Contribution to journal › Article